Crossbeta Biosciences receives EuroTrans-Bio Grant
Crossbeta Biosciences’ technology enables to study and specifically target protein species that cause or aggravate misfolded protein diseases such as Alzheimer’s Disease. Targeting these disease-specific misfolded proteins and inhibiting their negative effects creates novel treatment possibilities for these diseases.
Guus Scheefhals, CEO of Crossbeta Biosciences, said: “We are pleased with this recognition and financial support from EuroTrans-Bio for our Alzheimer’s Disease program and proud of the high ranking that our project obtained. This grant further strengthens our motivation to find a cure for this highly debilitating disease.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.